Achieve Life Sciences, Inc. (ACHV) vs 4D Molecular Therapeutics, Inc. (FDMT)
A side-by-side comparison of Achieve Life Sciences, Inc. and 4D Molecular Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ACHV
Achieve Life Sciences, Inc.
$7.14HealthcareDelayed quote: Oct 6, 2026, 3:00 PM EDT
FDMT
4D Molecular Therapeutics, Inc.
$12.79HealthcareDelayed quote: Oct 6, 2026, 3:00 PM EDT
Total return — ACHV vs FDMT
growth of $100 · dividends reinvested · last 6yACHV -7.6% (-1.3%/yr)FDMT -68.1% (-17.3%/yr)ACHV compounded faster over this window
ACHV FDMT
ACHV vs FDMT: by the numbers
- •ACHV is the larger company ($732M vs $669M market cap).
- •Both run net losses; ACHV's is the smaller (0.00% vs -194.74% net margin).
Metrics side by side
Valuation
| Metric | ACHV | FDMT |
|---|---|---|
| P/S ratio | N/A | 7.27 |
| P/B ratio | N/A | 1.64 |
Profitability
| Metric | ACHV | FDMT |
|---|---|---|
| Gross margin | 0.00% | 91.05% |
| Operating margin | 0.00% | -187.24% |
| Net margin | 0.00% | -194.74% |
| ROE | N/A | -43.95% |
| ROIC | N/A | -44.30% |
Growth (annualized)
| Metric | ACHV | FDMT |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 31.93% |
| Total return CAGR (5Y) | -4.33% | -13.08% |
Frequently asked
- How have ACHV and FDMT total returns compared?
- Over the past 5 years, ACHV delivered -4.33% and FDMT delivered -13.08% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Achieve Life Sciences ROE4D Molecular Therapeutics ROEAchieve Life Sciences operating margin4D Molecular Therapeutics operating marginAchieve Life Sciences revenue growth4D Molecular Therapeutics revenue growthAchieve Life Sciences free cash flow4D Molecular Therapeutics free cash flow
Achieve Life Sciences & 4D Molecular Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.